PS1383 A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA‐RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01–16)

Abstract

Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single‐agent treatment in phase I/II studies in conjunction with observations that IMiD®‐treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof‐of principal immune‐oncology (IO) approach in a minimally pre‐treated MM population.Aims:To establish the clinical benefit rate (CBR) of KappaMab alone (Stage 1) and in combination with lenalidomide (LEN) and low dose dexamethasone (DEX) (Stage 2). Secondar..